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Background: von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome in which the patients develop
retinal and central nervous system hemangioblastomas, pheochromocytomas and clear-cell renal tumors. The
autosomal dominant disease is caused by mutations in the VHL gene.
Methods: VHL mutational analysis was carried out by sequencing of the coding sequence and by multiplex
ligation-dependent probe amplification analysis. The functional consequence of the variants was investigated using
in silico prediction tools.
Results: A total of 289 probands suspected of having VHL syndrome have been screened for mutations in the VHL
gene. Twenty-six different VHL mutations were identified in 36 families including one in-frame duplication, two
frame-shift mutations, four nonsense mutations, twelve missense mutations, three intronic mutations and four large
genomic rearrangements. Three of these mutations (c.319 C> T, c.342_343dupGGT and c.520_521dupAA) were
novel.
Conclusions: In this study we report the VHL germ-line mutations found in Danish families. We found three novel
VHL mutations where two were classified as pathogenic and the latter was classified as a variant of unknown
significance. Together, our findings contribute to the interpretation of the potential pathogenicity of VHL germ-line
mutations.
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von Hippel-Lindau (VHL) disease (OMIM 193300) is a
dominantly inherited cancer syndrome characterized by
central nervous system and retinal hemangioblastomas,
clear cell renal carcinoma, neuroendocrine tumors and
cysts of the pancreas, pheochromocytomas, endolym-
phatic sac tumors and/or papillary cystadenomas of the
epididymis and broad ligament [1]. Patients without
pheochromocytomas are classified as VHL type 1 and
those with pheochromocytoma as VHL type 2. Type 2
patients are further divided into three subgroups: type
2A patients with low risk of renal cell carcinomas, type
2B patients with high risk of renal cell carcinomas and
type 2 C patients with isolated pheochromocytoma [2].
von Hippel-Lindau disease is caused by germ-line
mutations in the VHL tumor suppressor gene located on* Correspondence: tvoh@rh.dk
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distribution, and reproduction in any mediumthe short arm of chromosome 3 (3p25-26). The gene
spans 10 kb, is composed of three exons (Figure 1) and
encodes two proteins (pVHL19 and pVHL30) [3-5]. The
complete VHL protein consists of 214 amino acids and
has two structural domains: the α-domain and the
β-domain [6].
The best characterized function of pVHLs is its role as a
substrate recognition component of the E3 ubiquitin pro-
tein ligase complex comprising pVHL, Elongin C, Elongin
B, Cullin 2 and Rbx1. In this complex, pVHL targets the
α-subunit of hypoxia inducible factor 1 (HIF-1α) and hyp-
oxia inducible factor 2 (HIF-2α, also known as EPAS1)
transcription factors for ubiquitin-mediated proteolysis.
The HIF transcription factors are involved in coordination
of the cellular response to hypoxia and in transcriptional
regulation of hypoxia inducible genes, including VEGF,
PDGF, TGFα and EPO. pVHL inactivation leads to
stabilization of HIF-1 and HIF-2 and subsequent tran-
scriptional activation of HIF-induced target genes [2].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 von Hippel-Lindau gene and protein structure. A) The VHL gene comprises three exons (gray). Nucleotide number is indicated
above the gene structure. B) The VHL protein structure with (GXEEX)8 repeat motif (pink), α-domain (purple) and β-domain (blue). Codon number
is indicated below the protein structure. The eleven residues subjected for missense mutations are indicated below the figure.
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patients suspected of having VHL disease. The clinical
characterization of the Danish VHL mutation carriers
has recently been published [7,8] and in this study we




The national Danish guidelines recommend mutational
VHL screening when a patient 1) exhibits at least two of
the following VHL manifestations: familial history of
renal cancers, paragangliomas, hemangioblastomas,
endolymphatic sac tumors, neuroendocrine tumors,
cysts of the pancreas and/or pheochromocytomas 2) has
one VHL affected first degree relative and exhibits at
least one of the mentioned manifestations [9]. Following
verbal and written consent blood samples were collected
from the probands. All family relatives are offered pre-
symptomatic testing and genetic counseling.
VHL screening
Genomic DNA was purified from whole blood using
either the QIAamp DNA mini kit (Qiagen, Hilden,
Germany) or Maxwell 16 blood DNA purification kit
(Promega, Stockholm, Sweden) according to manufac-
turer’s instructions. The VHL exons were amplified using
intronic primer pairs flanking each exon (Table 1) and
the PCR products were subsequently sequenced usingTable 1 Forward and reverse primers used for PCR
amplification of the VHL gene
Forward Primer Reverse Primer
Exon 1 5’-gcgcgcgaagactacggaggt-3’ 5’-gaatgctctgacgcttac-3’
Exon 2 5’-gtggctctttaacaacctttgct-3’ 5’-cctgtacttaccacaacaaccttatc-3’
Exon 3 5’-gtggaccctagtctgtcactgagg-3’ 5’-agactcatcagtaccatcaaaag-3’an ABI3730 DNA analyzer (Applied Biosystems, Foster
City, CA). Moreover, genomic DNA was examined for
large genomic rearrangements by multiplex ligation-
dependant probe amplification (MLPA) analysis using the
salsa MLPA P016 VHL kit (MRC-Holland, Amsterdam,
Holland). All sequence variants were verified in an inde-
pendent blood sample. VHL variants are numbered
according to accession number [GenBank: NM_000551]
following the guidelines from the Human Genetic Vari-
ation Society (www.hgvs.org/mutnomen).
In silico analysis
In silico prediction of the functional consequence of the
missense variants was performed using the web-based
program Align GVGD [10]. Align GVGD grades of > =
C25 were considered likely deleterious. The following
three splice site prediction programs were used to pre-
dict the variants influence on splicing pattern: www.
fruitfly.org/seq_tools/splice.html [11], www.cbs.dtu.dk/
services/NetGene2 [12] and www.umd.be/SSF [13]. The
genomic sequence spanning the intron mutations was
submitted according to the guidelines of each program
and default settings were used in all predictions.
Results and discussion
Until August 2011, 289 Danish patients had been screened
for mutations in the VHL gene by direct sequencing and
MLPA analysis. Germ-line mutations were detected in 36
families and the mutations were distributed widely
throughout the gene except for the first ~60 amino acids
(Figure 1). The pathogenicity of the 26 different mutations
found in the VHL gene were classified using published
data and in silico prediction analysis (Table 2).
In-frame deletion, frame-shift and nonsense mutations
The novel c.342_343dupGGT mutation is an in-frame du-
plication inserting a glycine residue between glycine-114
Table 2 VHL mutations identified in Danish patients with VHL suspected disease
Family ID Exon Nucleotide Protein In silico Interpretation References
04012 c.1-?_340+ ?del Pathogenic [14,15]
04013
04231
00117 c.1-?_463+ ?del Pathogenic [14]
04178
00108 1 c.194 C> T p.Ser65Leu C65 Pathogenic [14,16]
00118 1 c.194 C>G p.Ser65Trp C65 Pathogenic [14-17]
04025
00116 1 c.239 G> T p.Ser80Ile C15 Pathogenic [14-19]
04268 1 c.257 C> T p.Pro86Leu C0 Pathogenic [15-17]
00101 1 c.278 G>A p.Gly93Asp C0 Pathogenic [14,16]
00113 1 c.293A>G p.Tyr98Cys C65 Pathogenic [15,20]
00107 1 c.319 C> T p.Arg107Cys C25 Pathogenic Novel
00109 1 c.337 C> T p.Arg113X Pathogenic [21]
04283 c.340 + 5 G>C Polymorphism [17,22,23]
00121 1 c.342_343dupGGT p.Gly114_His115insGly Unknown Novel




00107 2 c.353 T>C p.Leu118Pro C25 Pathogenic [16,17,24]
00102 2 c.407 T>C p.Phe136Ser C55 Pathogenic [16,17]
00104 2 c.433 C> T p.Gln145X Pathogenic [17]
04008 c.463 + 1 G> T Pathogenic [16,18]
04030 c.463 + 8 C> T Unknown [25]
04163




00121 3 c.481 C> T p.Arg161X Pathogenic [14,16,18,22]
04015 3 c.488 T>A p.Leu163His C0 Pathogenic [22]
00123 3 c.496 G> T p.Val166Phe C0 Pathogenic [14,16,17]
00106 3 c.499 C> T p.Arg167Trp C65 Pathogenic [16-18,24]
00112 3 c.520_521dupAA p.Asn174LysfsX29 Pathogenic Novel
04026 3 c.548 C>A p.Ser183X Pathogenic [14,16]
04024 3 c.606dupA p.Gln203ThrfsX53 Pathogenic [17]
In silico predictions was performed using the web-based program Align GVGD and grades above 25 was considered likely deleterious.
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protein. The GGT duplication is located in the 5’ end of
exon 2 close to the splice acceptor site. However, in silico
analysis did not predict any major changes in the splicing
pattern and thus the pathogenicity of the p.Gly114_Hi-
s115insGly mutation remains unknown. Since only the
proband was screened it has not been possible to examine
if this specific variant co-segregates with VHL disease.The two frame-shift mutations, c.520_521dupAA
(p.Asn174LysfsX28) and c.606dupA (p.Gln203ThrfsX55),
both located in exon 3, introduce two new termination
codons. The c.520_521dupAA frame-shift leads to a
truncated pVHL, whereas the c.606dupA frame-shift
results in a larger pVHL. To our knowledge only the
c.606dupA mutations has been described before [17],
however both mutations are classified as pathogenic.
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(p.Arg113X), exon 2 (p.Gln145X) and exon 3 (p.Arg161X
and p.Ser163X) have previously been reported and are all
classified as pathogenic [14,16-18,21,22].Missense mutations
Seven of the twelve identified missense mutations were
located in exon 1, two in exon 2 and three in exon 3
(Figure 1). Besides these, a known polymorphism
(c.74 C>T, p.Pro25Leu) [19,26] was found in six unre-
lated Danish families.
Two mutations changed the serine-65 residue to leu-
cine (p.Ser65Leu) and tryptophan (p.Ser65Trp), respect-
ively. The p.Ser65Leu mutation was found in several
members of the same family; four mutation- or obligate
carriers were diagnosed with VHL disease between 27
and 46 years, five carriers were unaffected (0–22 years),
two obligate carriers died unaffected (85 and 88 years)
and the parents of three obligate carriers died unaffected
(70 and 92 years). The p.Ser65Trp mutation was found
in two unrelated individuals with VHL related disease.
Serine-65 mutations are known to disrupt binding of
pVHL to HIF-1α [27] and are observed in several type 1
VHL affected families [14,15,17]. In silico analysis pre-
dicted a pathogenic effect (class C65) of both the
p.Ser65Leu and the p.Ser65Trp mutations supporting
the hypothesis that both mutations are pathogenic. The
observation of unaffected mutation carriers may indicate
reduced penetrance of the p.Ser65Leu mutation or the
co-inheritance of a protective genetic modifier in some
family members.
The p.Ser80Ile mutation was found in a single patient.
Although in silico analysis classify the mutation of low
clinical significance (class C15) the mutation is expected
to disrupt the three-dimensional structure of pVHL [19]
indicating that the mutation is pathogenic. The mutation
has previously been identified in a Hungarian type 2
VHL affected family where all members except the pro-
band’s mother showed clinical manifestations of VHL
disease [19].
The p.Pro86Leu mutation was found in one individual
and the p.Gly93Asp mutation was found in eight mem-
bers of one family. The mutations have previously been
associated with type 1 and type 2 VHL disease, respect-
ively [14,16,17]. The two mutations are both located in
the β-domain of pVHL (Figure 1) where the proline-86
residue is important for the structural integrity of the β
sandwich [6]. Moreover, the p.Pro86Leu mutation was
reported as a VHL hotspot [6,28]. These findings indi-
cate a pathogenic role of the two missense mutations re-
gardless of the result of the in silico analysis that
predicted the mutations to be without clinical signifi-
cance (class 0).The p.Tyr98Cys missense mutation was found in two
patients from the same family and has previously been
associated with type 2 VHL disease [15]. Another germ-
line mutation at tyrosine-98 (p.Tyr98His) was reported
as a German founder mutation [20]. The tyrosine-98
residue is located on the surface of the β-sandwich [6]
and in silico analysis predicted the mutation to be of
high clinical significance (class C65).
Both a mother and her son were found to carry two
VHL missense mutations (p.Arg107Cys and p.Leu118-
Pro) proving that both mutations are present on the
same allele. Changes of the arginine-107 residue to gly-
cine and histidine have previously been reported [18,29]
whereas the p.Arg107Cys missense mutation is novel.
The p.Leu118Pro mutation has been associated with
type 1 VHL disease [24]. Hence, clinical findings and
Align GVGD classifications (class C25) indicates a
pathogenic role of both mutations although the contri-
bution of each mutation to the phenotype is unknown.
The p.Phe136Ser mutation was found in a single pa-
tient. This mutation has previous been associated with
type 1 VHL disease [16,17] and together with in silico
analysis (class C55) this suggest that the mutation is
pathogenic.
The p.Leu163His, p.Val166Phe and p.Arg167Trp
mutations are all located in the α-domain of pVHL
(Figure 1). In silico analysis does not indicate a patho-
genic effect of p.Leu163His and p.Val166Phe (class C0).
However, Leucine-163 and valine-166 are contact resi-
dues when pVHL binds to elongin C [30] and mutations
at the leucine-163 residue have shown to impair the
ability of pVHL to target HIF-1α for destruction [31].
These findings suggest that both mutations are patho-
genic. Arginine-167 has a structural role in stabilizing
the H1 helix and the α-β domain interface and was pre-
viously reported as the most frequently mutated residue
in VHL [6]. The importance of arginine-167 is supported
by in silico analysis classifying the p.Arg167Trp mutation
as pathogenic (class C65).
Intronic mutations
We identified three intronic mutations located in intron 1
(c.340+ 5 G>C) and intron 2 (c.463 + 1 G>T and
c.463+ 8 C>T). The c. 340+ 5 G>C intronic mutation
was previously observed in a VHL family in trans with a
pathogenic VHL mutation [22,23] suggesting it is a benign
polymorphism. This is supported by in silico analysis
showing no major changes in splicing pattern. The
c.463 + 1 G>T intronic mutation disrupt the highly con-
served splice donor site [32] and in silico analysis pre-
dicted skipping of VHL exon 2. Combined with an earlier
described association with type 1 VHL disease [18] this
clearly suggests a pathogenic effect of this mutation. The
c.463 + 8 C>T mutation was found in two unrelated
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variant of unknown significance [25]. In silico analysis sug-
gested no major changes in the splicing pattern indicating
that the variant might be a benign polymorphism. How-
ever, functional studies or analysis of co-segregation are
needed to confirm this.Large genomic rearrangements
Large genomic rearrangements were identified in thir-
teen Danish families. Deletion of exon 1 (c.1-?_340 +
?del) was found in three families, deletion of both exon
1 and 2 (c.1-?_463 + ?del) was found in two families
whereas deletion of either exon 2 (c.341-?_463 + ?del) or
exon 3 (c.464-?_642 + ?del) was found in four families
each. Although the exact break point of the four differ-
ent deletions is unknown similar deletions have previ-
ously been reported as pathogenic [14,15,18]. Large
genomic rearrangements leading to truncated versions
of pVHL are primarily associated with type 1 VHL dis-
ease [33].
Altogether, we found 33.4% missense mutations, 11.1%
nonsense mutations, 11.1% intronic mutations, 2.7% in-
frame mutations, 5.6% frame-shift mutations and 36.1%
large genomic rearrangement. This spectrum of muta-
tions is in concordance with a recently published study
[34], although we found less missense mutations (33.4%
vs 52%) and a higher prevalence of large genomic rear-
rangements (36.1% vs 11%).Conclusions
In conclusion, we have screened 289 Danish probands
with VHL suspected disease and identified 26 mutations
in 36 families. We classified all large genomic rearrange-
ments and all nonsense- and missense mutations as
pathogenic. The two frame-shift mutations were classi-
fied as pathogenic, whereas the in-frame duplication was
classified as a variant of unknown significance. Of the
three intron variants found, one was a benign poly-
morphism, one was pathogenic and one was a variant of
unknown significance. Of these mutations the missense
mutation c.319 C>T (p.Arg107Cys), the in-frame dupli-
cation c.342_343dupGGT (p.GlyHis_His115insGly) and
the frame-shift mutation c.520_521dupAA (p.Asn174-
LysfsX29) were found to be novel.
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